姓名：山长亮
职称：教授 南开大学百名青年学科带头人
学科方向：肿瘤药理、分子生物学和细胞生物学
研究方向：肿瘤代谢酶表观调控与化学干预
通讯地址：天津市津南区同砚路38号南开大学药学院102室
电子邮件：changliangshan@nankai.edu.cn
教师简介：
教育背景
2011年 获南开大学 生物化学与分子生物学 博士
2006年 获鲁东大学 生物技术 本科
工作经历
2018年12月~至今 南开大学药学院 教授 博导
2015年6月~2018年11月 暨南大学生物医学转化研究院 研究员 博导
2015年1月~2015年 5月 上海药物研究所 客座研究员
2011年9月~2014年12月 美国Emory 大学医学院 博后
个人专长
山长亮博士长期从事肿瘤代谢酶表观调控与化学干预研究。以通讯（含共同）在Cell Death & Differentiation, Acta Pharmaceutica Sinica B, Advanced Science, Theranostics, J Exp Clin Cancer Res, MedComm, Acta Pharmacol Sin, Clinical and Translational Medicine, Cancer Letter, Biochemical Pharmacology, Cell Death & Disease, Carcinogenesis, Journal of Medicinal Chemistry和 European Journal of Medicinal Chemistry等上发表学术论文20余篇，总引用>3000次，h-index=29。
学术兼职
中国抗癌协会抗癌药物专业委员会第六、七届委员会委员
中国抗癌协会肿瘤标志专业委员会青年委员
中国细胞生物学学会肿瘤细胞生物学学会分会委员
中国细胞生物学学会细胞代谢分会委员
中国抗癌协会肿瘤细胞代谢分会委员
中国抗癌协会非编码RNA与肿瘤研究专家委员会常委
获奖情况
2020年获南开大学第九届“良师益友”十佳奖
2022/2023年获南开大学优秀硕士学位论文指导教师称号
2019/2020-2021/2021-2022/2022-2023年度校级技术安全优秀实验室
2024年南开大学优秀班导师
代表性论文：（*通讯作者#第一作者）
1. Qiao Y#, Wang C#, Liu H#, Sun H#, Zhao H, Zhang Q, Dai X, Sun M, Wang T, He T, Li Z, Li Y, Xue J, Zhang C*, Shan C*, Zhang S*. USP30 senses serine/glycine levels to regulate serine biosynthesis and colorectal tumorigenesis by deubiquitinating FTO. Cell Death Differ. 2026 Feb 6. doi: 10.1038/s41418-026-01680-2.
2. Wang J#, Dai X#, Liu H#, Hua S, Chang H, Sun H, Sun M, Zhao H, Ni K, Xie F, Qiao Y, Gao Q, Yu C, Zhang Q, Guo J, Zhang C*, Zhang S*, Shan C*. HPD is an m6A Methyltransferase that Protects Colorectal Cancer Cells from Ferroptotic Cell Death by m6A Methylating SLC7A11/GPX4. Adv Sci (Weinh). 2025 Nov 29:e08541. doi: 10.1002/advs.202508541.
3. Xie F#, Zhang H#, Dai X#, Tu M#, Yu C, Liu L, Guo Y, Sun H, Gao Q, Wang J, Sun M, Zhang Q, Wang T, He T, Li Z, Li Y, Wang T, Zhao J, Chen Z, Zhang C, Zhang S*, Shan C*. HPD is an RNA-Binding Protein Sustaining Ovarian Cancer Cell Glycolysis, Tumor Growth, and Drug Resistance. Adv Sci (Weinh). 2025 Jun 10:e03999.
4. Zhang R#, Sun M#, Xiao X, Li H, Jiang L, Chen J, Yang M, Yao X, Shan C*, Zhou L*. Discovery of N-(1,3,4-Thiadiazol-2-yl)amide Derivatives as Uncompetitive Inhibitors of 6-Phosphogluconate Dehydrogenase. J Med Chem. 2025 Aug 14;68(15):15403-15421.
5. Sun M#, Yan Q#, Zhai X#, Dai X, Yang C, Zhao H, Lai S, Wang J, Li L, Li Z, Li Y, Wang T, He T, Xue J, Jia Z*, Zhang C*, Zhang S*, Shan C*. The non-metabolic function of 6PGD coordinates CCNA2 and HMGA2 expression to drive colorectal cancer progression and drug response. J Exp Clin Cancer Res. 2025 Jul 3;44(1):186.
6. Hu X#, Tang X#, Tian X, Lv X, Zhang Y, Pang Y, Deng W, Wang Y, Shan C*, Shang L*. Discovery of indole analogue Tc3 as a potent pyroptosis inducer and identification of its combination strategy against hepatic carcinoma. Theranostics. 2025; 15(4): 1285-1303.
7. Wei Y#, Sun MM#, Zhang RL#, Wang L, Yang LH, Shan CL*, Lin JP*. Discovery of novel dual-target inhibitors of LSD1/EGFR for non-small cell lung cancer therapy. Acta Pharmacol Sin. 2025 Jan 3. doi: 10.1038/s41401-024-01439-w.
8. Zhang W*, Wang J, Shan C*. The eEF1A protein in cancer: Clinical significance, oncogenic mechanisms, and targeted therapeutic strategies. Pharmacol Res. 2024 Jun;204:107195.
9. Zhang H#, Xie F#, Yuan X#, Dai X#, Tian Y, Sun M, Yu S, Cai J, Sun B, Zhang W*, Shan C*. Discovery of a nitroaromatic nannocystin with potent in vivo anticancer activity against colorectal cancer by targeting AKT1. Acta Pharmacol Sin. 2024 May;45(5):1044-1059.
10. Qiao Y, Su M, Zhao H, Liu H, Wang C, Dai X, Liu L, Liu G, Sun H, Sun M, Wang J, Li Z, Fan J, Zhang Q, Li C, Situ F, Xue J, Jia Z*, Zhang C*, Zhang S*, Shan C*. Targeting FTO induces colorectal cancer ferroptotic cell death by decreasing SLC7A11/GPX4 expression. J Exp Clin Cancer Res. 2024 Apr 10;43(1):108. (高被引论文)
11. Xie F#, Zhang H#, Zhu K#, Jiang CS#, Zhang X, Chang H, Qiao Y, Sun M, Wang J, Wang M, Tan J, Wang T, Zhao L, Zhang Y, Lin J, Zhang C, Liu S, Zhao J*, Luo C*, Zhang S*, Shan C*. PRMT5 promotes ovarian cancer growth through enhancing Warburg effect by methylating ENO1. MedComm (2020). 2023 Mar 28;4(2):e245.
12. Sun M#, Li L#, Niu Y#, Wang Y, Yan Q, Xie F, Qiao Y, Song J, Sun H, Li Z, Lai S, Chang H, Zhang H, Wang J, Yang C, Zhao H, Tan J, Li Y, Liu S, Lu B, Liu M, Kong G, Zhao Y, Zhang C, Lin SH*, Luo C*, Zhang S*, Shan C*. PRMT6 promotes tumorigenicity and cisplatin response of lung cancer through triggering 6PGD/ENO1 mediated cell metabolism. Acta Pharm Sin B. 2023 Jan;13(1):157-173. (高被引论文/封底论文)
13. Wang J, Qiao Y, Sun M, Sun H, Xie F, Chang H, Wang Y, Song J, Lai S, Yang C, Li X, Liu S, Zhao X, Ni K, Meng K, Zhang S*, Shan C*, Zhang C*, FTO promotes colorectal cancer progression and chemotherapy resistance via demethylating G6PD/PARP1.Clin Transl Med.2022 Mar;12(3):e772.
14. Sheng H, Li Z, Su S, Sun W, Zhang X, Li L, Li J, Liu S, Lu B, Zhang S*, Shan C*. YTH domain family 2 promotes lung cancer cell growth by facilitating 6-phosphogluconate dehydrogenase mRNA translation. Carcinogenesis. 2020 Jul 10;41(5):541-550.2 (高被引论文).
15. Li Y#, Liang R#, Sun M#, Li Z, Sheng H, Wang J, Xu P, Liu S, Yang W, Lu B, Zhang S*, Shan C*. AMPK-dependent phosphorylation of HDAC8 triggers PGM1 expression to promote lung cancer cell survival under glucose starvation. Cancer Lett. 2020 May 28;478:82-92.2.